宣泰医药注射用硫酸艾沙康唑获批准

Core Viewpoint - Xuantai Pharmaceutical (688247) has received approval from the National Medical Products Administration for the marketing of injectable isavuconazole, which is expected to enhance the company's product line and competitiveness, positively impacting future operating performance [1] Group 1 - The company announced the approval of injectable isavuconazole on January 6 [1] - The approval is seen as a strategic move to enrich the company's product offerings [1] - The introduction of this product is anticipated to have a positive effect on the company's future financial performance [1]